KaloBios to Reduce Workforce, Explore Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
KaloBios Pharma (KBIO) to Cut 61% of Workforce and Explore Options
November 5, 2015 5:35 PM ESTKaloBios Pharma (NASDAQ: KBIO) announced that it will reduce its workforce as part of a plan to reduce operating costs. This action will reduce the company's workforce by approximately 17 employees (or 61%), and will focus the company's resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.
"While this decision was extremely difficult, aligning and managing... More
